Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $26,130.00 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Yeu Lin sold 390 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $26,130.00. Following the completion of the transaction, the insider owned 23,308 shares of the company’s stock, valued at $1,561,636. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Wednesday, March 18th, Elizabeth Yeu Lin sold 379 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $68.71, for a total transaction of $26,041.09.
• On Tuesday, March 17th, Elizabeth Yeu Lin sold 375 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $69.42, for a total transaction of $26,032.50.

Tarsus Pharmaceuticals Stock Down 3.4%

Shares of NASDAQ:TARS opened at $64.51 on Friday. The firm has a fifty day moving average price of $69.12 and a two-hundred day moving average price of $70.30. The company has a market cap of $2.75 billion, a price-to-earnings ratio of -39.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. Tarsus Pharmaceuticals, Inc. has a one year low of $38.51 and a one year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The firm had revenue of $151.67 million during the quarter, compared to the consensus estimate of $144.56 million. Analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

Analyst Ratings Changes

A number of analysts have recently issued reports on TARS shares. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Zacks Research lowered shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Guggenheim boosted their price target on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, Lifesci Capital raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.83.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Deep Track Capital LP lifted its holdings in shares of Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after acquiring an additional 1,250,000 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Tarsus Pharmaceuticals by 34.1% in the 4th quarter. Janus Henderson Group PLC now owns 1,930,325 shares of the company’s stock valued at $158,062,000 after purchasing an additional 491,326 shares in the last quarter. Norges Bank bought a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $19,095,000. M&T Bank Corp raised its position in Tarsus Pharmaceuticals by 11,730.0% in the 4th quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock worth $35,791,000 after purchasing an additional 433,424 shares during the period. Finally, MPM Bioimpact LLC purchased a new position in Tarsus Pharmaceuticals in the 2nd quarter worth $13,834,000. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.